Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease

  • Verheijen, Jan
  • Van den Bossche, Tobi
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Bettens, Karolien
  • Mateiu, Ligia
  • Dillen, Lubina
  • Cras, Patrick|||0000-0002-7265-7429
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
The sortilin-related receptor 1 (SORL1) gene has been associated with increased risk for Alzheimer's disease (AD). Rare genetic variants in the SORL1 gene have also been implicated in autosomal dominant early-onset AD (EOAD). Here we report a large-scale investigation of the contribution of genetic variability in SORL1 to EOAD in a European EOAD cohort. We performed massive parallel amplicon-based re-sequencing of the full coding region of SORL1 in 1255 EOAD patients and 1938 age- and origin-matched control individuals in the context of the European Early-Onset Dementia (EOD) consortium, originating from Belgium, Spain, Portugal, Italy, Sweden, Germany, and Czech Republic. We identified six frameshift variants and two nonsense variants that were exclusively present in patients. These mutations are predicted to result in haploinsufficiency through nonsense-mediated mRNA decay, which could be confirmed experimentally for SORL1 p.Gly447Argfs*22 observed in a Belgian EOAD patient. We observed a 1.5-fold enrichment of rare non-synonymous variants in patients (carrier frequency 8.8 %; SkatOMeta p value 0.0001). Of the 84 non-synonymous rare variants detected in the full patient/control cohort, 36 were only detected in patients. Our findings underscore a role of rare SORL1 variants in EOAD, but also show a non-negligible frequency of these variants in healthy individuals, necessitating the need for pathogenicity assays. Premature stop codons due to frameshift and nonsense variants, have so far exclusively been found in patients, and their predicted mode of action corresponds with evidence from in vitro functional studies of SORL1 in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2

  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Monté, Gemma C.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Falcon, Carles
  • Tucholka, Alan
  • Rojas Codina, Santiago|||0000-0003-1834-7822
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Kleinberger, Gernot|||0000-0002-5811-8226
  • Haass, Christian|||0000-0002-4869-1627
  • Molinuevo, José Luis|||0000-0003-0485-6001
Among other metabolic functions, the apolipoprotein E (APOE) plays a crucial role in neuroinflammation. We aimed at assessing whether APOE ε4 modulates levels of glial cerebrospinal fluid (CSF) biomarkers and their structural cerebral correlates along the continuum of Alzheimer's disease (AD). Brain magnetic resonance imaging (MRI) scans were acquired in 110 participants (49 control; 19 preclinical; 27 mild cognitive impairment [MCI] due to AD; 15 mild AD dementia) and CSF concentrations of YKL-40 and sTREM2 were determined. Differences in CSF biomarker concentrations and interactions in their association with gray-matter volume according to APOE ε4 status were sought after. Preclinical and MCI carriers showed higher YKL-40 levels. There was a significant interaction in the association between YKL-40 levels and gray-matter volume according to ε4 status. No similar effects could be detected for sTREM2 levels. Our findings are indicative of an increased astroglial activation in APOE ε4 carriers while both groups displayed similar levels of CSF AD core biomarkers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease

  • De Roeck, Arne
  • Van den Bossche, Tobi
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Verheijen, Jan
  • De Coster, Wouter
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Dillen, Lubina
  • Baradaran-Heravi, Yalda
  • Heeman, Bavo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Gómez-Tortosa, Estrella
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Borroni, Barbara|||0000-0001-9340-9814
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Santana, Isabel|||0000-0002-8114-9434
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Koutroumani, Maria
  • Matej, Radoslav|||0000-0002-6152-6343
  • Rohan, Zdenek|||0000-0003-3501-6179
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Cras, Patrick|||0000-0002-7265-7429
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
Premature termination codon (PTC) mutations in the ATP-Binding Cassette, Sub-Family A, Member 7 gene (ABCA7) have recently been identified as intermediate-to-high penetrant risk factor for late-onset Alzheimer's disease (LOAD). High variability, however, is observed in downstream ABCA7 mRNA and protein expression, disease penetrance, and onset age, indicative of unknown modifying factors. Here, we investigated the prevalence and disease penetrance of ABCA7 PTC mutations in a large early onset AD (EOAD)-control cohort, and examined the effect on transcript level with comprehensive third-generation long-read sequencing. We characterized the ABCA7 coding sequence with next-generation sequencing in 928 EOAD patients and 980 matched control individuals. With MetaSKAT rare variant association analysis, we observed a fivefold enrichment (p = 0.0004) of PTC mutations in EOAD patients (3%) versus controls (0.6%). Ten novel PTC mutations were only observed in patients, and PTC mutation carriers in general had an increased familial AD load. In addition, we observed nominal risk reducing trends for three common coding variants. Seven PTC mutations were further analyzed using targeted long-read cDNA sequencing on an Oxford Nanopore MinION platform. PTC-containing transcripts for each investigated PTC mutation were observed at varying proportion (5-41% of the total read count), implying incomplete nonsense-mediated mRNA decay (NMD). Furthermore, we distinguished and phased several previously unknown alternative splicing events (up to 30% of transcripts). In conjunction with PTC mutations, several of these novel ABCA7 isoforms have the potential to rescue deleterious PTC effects. In conclusion, ABCA7 PTC mutations play a substantial role in EOAD, warranting genetic screening of ABCA7 in genetically unexplained patients. Long-read cDNA sequencing revealed both varying degrees of NMD and transcript-modifying events, which may influence ABCA7 dosage, disease severity, and may create opportunities for therapeutic interventions in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort

  • Verheijen, Jan
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Gijselinck, Ilse
  • Van den Bossche, Tobi
  • Dillen, Lubina
  • Heeman, Bavo
  • Gómez-Tortosa, Estrella
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Graff, Caroline|||0000-0002-9949-2951
  • Pastor, Pau|||0000-0002-7493-8777
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Clarimón, Jordi|||0000-0002-6824-6942
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Borroni, Barbara|||0000-0001-9340-9814
  • Matej, Radoslav|||0000-0002-6152-6343
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Cruts, Marc|||0000-0002-1338-992X
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Goeman, Johan
  • Nuytten, Dirk
  • Vandenbulcke, Mathieu
  • Santens, Patrick|||0000-0002-8886-9776
  • De Bleecker, J.
  • Sieben, Anne|||0000-0003-1278-6605
  • Dermaut, Bart
  • Versijpt, Jan|||0000-0002-8710-5715
  • Michotte, Alex|||0000-0002-5652-6859
  • Deryck, Olivier|||0000-0001-6720-5404
  • Bergmans, Bruno|||0000-0002-1463-8262
  • Willems, Christiana
  • Ivanoiu, Adrian
  • Salmon, Eric|||0000-0003-2520-9241
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Bessi, Valentina|||0000-0002-6176-3584
  • Bagnoli, Silvia
  • Santana, Isabel|||0000-0002-8114-9434
  • Simões do Couto, Frederico|||0000-0002-3916-2598
  • Martins, Madalena|||0000-0001-8360-6806
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Fratiglioni, Laura
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Rohan, Zdenek|||0000-0003-3501-6179
  • Razquín, Cristina|||0000-0003-3480-2645
  • Lorenzo, Elena
  • Iglesias, Elena
  • Seijo-Martínez, Manuel
  • Rene, Ramon
  • Gascon, Jordi
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Koutroumani, Maria
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Blesa, Rafael|||0000-0003-4026-2884
TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course. We performed targeted resequencing of TBK1 in 1253 early onset Alzheimer's disease (EOAD) patients from 8 European countries to investigate whether pathogenic TBK1 mutations are enriched among patients with clinical diagnosis of EOAD. Variant frequencies were compared against 2117 origin-matched controls. We identified only 1 LoF mutation (p.Thr79del) in a patient clinically diagnosed with Alzheimer's disease and a positive family history of ALS. We did not observe enrichment of rare variants in EOAD patients compared to controls, nor of rare variants affecting NFκB induction. Of 3 common coding variants, rs7486100 showed evidence of association (OR 1.46 [95% CI 1.13-1.9]; p-value 0.01). Homozygous carriers of the risk allele showed reduced expression of TBK1 (p-value 0.03). Our findings are not indicative of a significant role for TBK1 mutations in EOAD. The association between common variants in TBK1, disease risk and reduced TBK1 expression warrants follow-up in FTD/ALS cohorts.